Get the Stockscreener App
57.09
5.72%
3.09
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $57.09, with a volume of 1.44M.
It is up +5.72% in the last 24 hours and up +7.47% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$54.00
Open:
$54.89
24h Volume:
1.44M
Relative Volume:
0.65
Market Cap:
$8.95B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
60.73
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
+6.51%
1M Performance:
+7.47%
6M Performance:
-12.06%
1Y Performance:
-19.99%
1-Day Range:
$54.30
$57.43
1-Week Range:
$53.07
$57.43
52-Week Range:
$46.01
$80.95
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
57.09 | 8.35B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jul-09-25 | Initiated | TD Cowen | Buy |
| May-30-25 | Initiated | Wells Fargo | Overweight |
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Bio Techne Corporation Stock Flags Risk Zone in Volatility Index2025 Pullback Review & Momentum Based Trading Signals - thegnnews.com
Bio-Techne Stock: Analyst Estimates & Ratings - Barchart.com
How Bio Techne Corporation stock performs during market volatilityTrade Entry Report & Community Trade Idea Sharing - beatles.ru
What makes Bio Techne Corporation stock price move sharplyJuly 2025 Earnings & Expert Approved Momentum Ideas - thegnnews.com
Stock Analysis | Bio-Techne OutlookA Stock to Watch with Mixed Signals - AInvest
Bio-Techne: Key Dividend Information and Recent Developments Ahead of Ex-Dividend Date on Aug 18, 2025 - AInvest
Three Companies Trading Ex-Dividend on 8/18/25 - AInvest
Ex-Dividend Reminder: Bio-Techne, First Hawaiian and CNA Financial - Nasdaq
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates - GlobeNewswire Inc.
Bio-Techne's (NASDAQ:TECH) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Alignment Healthcare, Bio-Techne, Envista, iRhythm, and UFP Technologies Shares Skyrocket, What You Need To Know - Yahoo Finance
Bio-Techne Corporation shares rise 2.40% intraday as S&P 500, Nasdaq futures hit record highs. - AInvest
Bio-Techne's Q4 2025: Navigating Contradictions in NIH Funding, China Growth, and Revenue Outlook - AInvest
The 5 Most Interesting Analyst Questions From Bio-Techne’s Q2 Earnings Call - Yahoo Finance
Stock Market Rally: Revvity, Avantor, Azenta, Bio-Techne, Amneal Shares Surge Amid Fed Interest Rate Cut Hopes - AInvest
Revvity, Avantor, Azenta, Bio-Techne, and Amneal Shares Skyrocket, What You Need To Know - Yahoo Finance
TECH Q2 Deep Dive: Margin Pressures and Portfolio Shifts Amid Market Uncertainty - Yahoo Finance
Bio-Techne Earnings: Fourth-Quarter Results In-Line, but Volatile US Policy Is Hurting End Markets - Morningstar
Bio-Techne Leads Key Proteomic Reagent Markets, but Near-Term Challenges Loom - Morningstar
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls - MSN
Can Bio Techne Corporation disrupt its industryMaximum Leverage Stock Strategy - thegnnews.com
Bio-Techne Corp Q4 Earnings: Revenue Exceeds Estimates at $317M, Adjusted EPS Rises to $0.53, GAAP EPS Misses - AInvest
A Quick Look at Today's Ratings for Bio-Techne(TECH.US), With a Forecast Between $53 to $75 - 富途牛牛
Stocks making big moves yesterday: Bloomin' Brands, Bio-Techne, Snap, Grocery Outlet, and Paramount - Yahoo Finance
A Quick Look at Today's Ratings for Bio-Techne(TECH.US), With a Forecast Between $59 to $65 - 富途牛牛
Bio-Techne Corporation (NASDAQ:TECH) Q4 2025 Earnings Call Transcript - Insider Monkey
Bio-Techne Full Year 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Bio-Techne Exceeds Forecasts And Refines Its Focus On Growth - Finimize
Bio-Techne takes a hit on Exodx sale to Mdxhealth - BioWorld MedTech
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Bio-Techne's Q4 Fiscal 2025 Results Trigger 6.5% Share DeclineNews and Statistics - IndexBox
Why Bio-Techne (TECH) Shares Are Plunging Today - Yahoo Finance
Earnings call transcript: Bio-Techne Q4 2025 beats EPS forecasts - Investing.com
Bio-Techne Q2 2025 Financial Results: Revenue and EPS Surpass ExpectationsNews and Statistics - IndexBox
Bio-Techne Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Bio-Techne (NASDAQ:TECH) Exceeds Q2 Expectations - Yahoo Finance
Here's What Key Metrics Tell Us About Techne (TECH) Q4 Earnings - Nasdaq
Bio-Techne Q4 25 Earnings Conference Call At 9:00 AM ET - Nasdaq
Techne (TECH) Beats Q4 Earnings and Revenue Estimates - Nasdaq
Bio-Techne Corp (TECH) Q4 Earnings: Revenue Surpasses Estimates - GuruFocus
Bio-Techne Posts Loss In Q4 - Nasdaq
Bio-Techne earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Bio-techne declares quarterly dividend of $0.08 per share - Investing.com
Bio-techne declares quarterly dividend of $0.08 per share By Investing.com - Investing.com Canada
Bio-Techne Earnings Beat Estimates as Cell Therapy Division Drives Growth, Strategic Divestiture Announced - Stock Titan
Bio-Techne Releases Fourth Quarter Fiscal 2025 Results06.08.25News - Ariva
Bio-techne to sell exosome diagnostics business to mdxhealth By Investing.com - Investing.com South Africa
Bio-techne to sell exosome diagnostics business to mdxhealth - Investing.com
Bio-Techne Sells Prostate Cancer Test Business to Strengthen Core Operations: Strategic Shift Revealed - Stock Titan
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne - The Manila Times
ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine - Yahoo Finance
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bio Techne Corp Stock (TECH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Herr Amy E. | Director |
Aug 15 '25 |
Option Exercise |
0.00 |
279 |
0 |
2,255 |
| Kelderman Kim | Chief Executive Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
8,543 |
0 |
55,273 |
| Bohnen Shane | SVP - General Counsel |
Aug 15 '25 |
Option Exercise |
0.00 |
1,718 |
0 |
4,912 |
| McManus Matthew | President - Diag & Spatial Bio |
Aug 15 '25 |
Option Exercise |
0.00 |
2,637 |
0 |
5,615 |
| Geist William | PRESIDENT, PROTEIN SCIENCES |
Aug 15 '25 |
Option Exercise |
0.00 |
2,623 |
0 |
15,915 |
| HIGGINS JOHN L | Director |
Aug 07 '25 |
Option Exercise |
21.84 |
5,040 |
110,074 |
65,236 |
| Hippel James | CFO |
Jul 29 '25 |
Option Exercise |
44.33 |
168,620 |
7,474,925 |
275,230 |
| Kelderman Kim | Chief Executive Officer |
Jul 22 '25 |
Option Exercise |
44.33 |
48,176 |
2,135,642 |
90,379 |
| Kelderman Kim | Chief Executive Officer |
Jul 15 '25 |
Option Exercise |
44.33 |
36,132 |
1,601,732 |
75,136 |
| Herr Amy E. | Director |
Jun 09 '25 |
Option Exercise |
44.33 |
1,280 |
56,742 |
3,256 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):